{"success":true,"data":{"pressRelease":{"id":"43701","rtpr_id":"nNFC7nHVwC","ticker":"IBRX","exchange":"NASDAQ","all_tickers":["IBRX"],"title":"Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","published_at":"2026-05-22T16:00:13.339Z","article_body":"New York, New York--(Newsfile Corp. - May 22, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ:\nIBRX) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired ImmunityBio securities between\nJanuary 19, 2026 and March 24, 2026, both dates inclusive (the \"Class\nPeriod\"). Such investors are encouraged to join this case by visiting the\nfirm's site: bgandg.com/IBRX\n(https://api.newsfilecorp.com/redirect/wE0GMcBK5E).\n\nImmunityBio Case Details\n\nThe Complaint alleges that Defendants' statements were materially false and/or\nmisleading because they misrepresented and failed to disclose the following\nadverse facts pertaining to the Company's business, operations and prospects,\nwhich were known to Defendants or recklessly disregarded by them.\nSpecifically, the Complaint alleges that Defendants made false and/or\nmisleading statements and/or failed to disclose that:\n1. Defendant Soon-Shion materially overstated Anktiva's capabilities; and\n2. as a result, Defendants' statements about ImmunityBio's business,\noperations, and prospects were materially false and misleading and/or lacked a\nreasonable basis at all relevant times.\nWhat's Next for ImmunityBio Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/IBRX\n(https://api.newsfilecorp.com/redirect/gJRmVh57Lz), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in ImmunityBio\nyou have until May 26, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to ImmunityBio Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for ImmunityBio Securities Class\nAction?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/YEJLQcMODN), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/0pvgMFkxeq), X\n(https://api.newsfilecorp.com/redirect/RYDJ8tOQmy), Facebook\n(https://api.newsfilecorp.com/redirect/WAjBqtMLNr), or Instagram\n(https://api.newsfilecorp.com/redirect/qpgV2FKYJO).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/295073","article_body_html":"","raw_payload":{"data":{"id":"nNFC7nHVwC","title":"Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm","author":"Newsfile Corp","ticker":"IBRX","created":"2026-05-22T16:00:13.339Z","tickers":["IBRX"],"exchange":"NASDAQ","article_body":"New York, New York--(Newsfile Corp. - May 22, 2026) - Bronstein, Gewirtz &\nGrossman, LLC, a nationally recognized investor-rights law firm, announces\nthat a class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ:\nIBRX) and certain of its officers.\n\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired ImmunityBio securities between\nJanuary 19, 2026 and March 24, 2026, both dates inclusive (the \"Class\nPeriod\"). Such investors are encouraged to join this case by visiting the\nfirm's site: bgandg.com/IBRX\n(https://api.newsfilecorp.com/redirect/wE0GMcBK5E).\n\nImmunityBio Case Details\n\nThe Complaint alleges that Defendants' statements were materially false and/or\nmisleading because they misrepresented and failed to disclose the following\nadverse facts pertaining to the Company's business, operations and prospects,\nwhich were known to Defendants or recklessly disregarded by them.\nSpecifically, the Complaint alleges that Defendants made false and/or\nmisleading statements and/or failed to disclose that:\n1. Defendant Soon-Shion materially overstated Anktiva's capabilities; and\n2. as a result, Defendants' statements about ImmunityBio's business,\noperations, and prospects were materially false and misleading and/or lacked a\nreasonable basis at all relevant times.\nWhat's Next for ImmunityBio Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/IBRX\n(https://api.newsfilecorp.com/redirect/gJRmVh57Lz), or you may contact Peretz\nBronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein,\nGewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in ImmunityBio\nyou have until May 26, 2026, to request that the Court appoint you as lead\nplaintiff. Your ability to share in any recovery doesn't require that you\nserve as lead plaintiff.\n\nNo Cost to ImmunityBio Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for ImmunityBio Securities Class\nAction?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://api.newsfilecorp.com/redirect/YEJLQcMODN), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://api.newsfilecorp.com/redirect/0pvgMFkxeq), X\n(https://api.newsfilecorp.com/redirect/RYDJ8tOQmy), Facebook\n(https://api.newsfilecorp.com/redirect/WAjBqtMLNr), or Instagram\n(https://api.newsfilecorp.com/redirect/qpgV2FKYJO).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 | info@bgandg.com\n\nAttorney advertising.\nPrior results do not guarantee similar outcomes.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/295073"},"type":"article","timestamp":"2026-05-22T16:00:13.357207391Z","server_sent_at_ms":1779465613357},"received_at":"2026-05-22T16:00:13.436Z","source_url":"https://www.newsfilecorp.com/release/295073"},"analysis":{"id":"33137","press_release_id":"43701","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Bronstein, Gewirtz & Grossman LLC announced a class action lawsuit against ImmunityBio and certain officers, alleging securities law violations.\n\nThe complaint alleges that Defendant Soon-Shion materially overstated the capabilities of the company's lead asset, Anktiva.\n\nThe firm is soliciting investors who purchased shares between January 19, 2026, and March 24, 2026, to join the case or seek lead plaintiff status by May 26, 2026.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace","namedEntities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"},{"name":"Soon-Shion","role":"Defendant/Officer"}],"products":["Anktiva"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"ImmunityBio, Inc.","ticker":"IBRX"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Bronstein, Gewirtz & Grossman LLC. The release is marketing for the law firm, not an issuer disclosure. No certified class or settlement announced."},"tickerRelevance":{"others":[],"primary":"IBRX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Bronstein, Gewirtz & Grossman LLC announced a class action lawsuit against ImmunityBio and certain officers, alleging securities law violations.\n\nThe complaint alleges that Defendant Soon-Shion materially overstated the capabilities of the company's lead asset, Anktiva.\n\nThe firm is soliciting investors who purchased shares between January 19, 2026, and March 24, 2026, to join the case or seek lead plaintiff status by May 26, 2026.","key_figures":{},"named_entities":{"people":[{"name":"Peretz Bronstein","role":"Founding Partner, Bronstein, Gewirtz & Grossman LLC"},{"name":"Nathan Miller","role":"Client Relations Manager, Bronstein, Gewirtz & Grossman LLC"},{"name":"Soon-Shion","role":"Defendant/Officer"}],"products":["Anktiva"],"companies":[{"name":"Bronstein, Gewirtz & Grossman LLC","relationship":"plaintiff law firm"},{"name":"ImmunityBio, Inc.","ticker":"IBRX"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-22T16:02:01.441Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":46005,"modelName":"george-droid-qwen-72b"}}